Biological
TV005 clinical trials
Also written TV005.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
5 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 3 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 5
National Institute of Allergy and Infectious Diseases (NIAID) (4) · Beth Kirkpatrick (1)
Studies
Open first, then newest update. How each study uses TV005 is read from its arms, and is right about nine times in ten.
Testing it · 5
- Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, BangladeshCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT02678455Written as TV005 vaccine
- Dengue Controlled Human Infection Model in Dhaka, BangladeshActive, not recruitingPhase 2Beth KirkpatrickNCT05229354Written as TV005
- Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of AgeCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02879266Written as TetraVax-DV TV005
- Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02873260Written as TetraVax-DV-TV005
- Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02317900Written as TV005